| Excellent Outcomes in Feasibility Study of Radiation-Free Conditioning and Transplant in Pediatric Severe Aplastic Anemia |
|
Transplant Cell Therapy |
Aplastic Anemia |
| Evolving therapies for lower-risk myelodysplastic syndromes |
|
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
| Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
| Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| ESCALATing care? Eltrombopag in pediatric aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial |
|
EJHaem |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial |
|
eJHaem |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia |
|
Transplantation and Cellular Therapy |
Aplastic Anemia, Graft Versus Host Disease (GVHD) |
